stockrow
Saturday 7 November 2026
Export GERN’s income statement to Excel — free account
Geron Corporation
GERN Healthcare Biotechnology
Geron Corporation’s revenue for fiscal 2025 (year ended December 2025) was $183.9 million, up 138.8% from fiscal 2024.
- Revenue
- +27.5%
- EPS
- +106.7%
- Free cash flow
- +176.1%
- Total debt
- +0.99%
Quarter to September 2026, against a year earlier
0.98
0.03
+3.16%
Follow GERN
Alert me
Geron Corporation (GERN) P/E ratio
Geron Corporation has no meaningful P/E ratio: its trailing twelve-month earnings is negative. Over the past ten years it has ranged from 0.0× (November 2026) to 305× (September 2016) — the current reading is the lowest in ten years.
P/E ratio, daily
Embed this chart
Annual newest first
| Period | P/E ratio | Change |
|---|---|---|
| FY2025 | 0.0× | — |
| FY2024 | 0.0× | — |
| FY2023 | 0.0× | — |
| FY2022 | 0.0× | — |
| FY2021 | 0.0× | — |
| FY2020 | 0.0× | — |
| FY2019 | 0.0× | — |
| FY2018 | 0.0× | — |
| FY2017 | 0.0× | — |
| FY2016 | 0.0× | — |
Quarterly newest first
| Period | P/E ratio | Change |
|---|---|---|
| Sep 2026 | 0.0× | — |
| Jun 2026 | 0.0× | — |
| Mar 2026 | 0.0× | — |
| Dec 2025 | 0.0× | — |
| 43 more quarters | Free account |
Against its own ten years
Low 0.0×
High 305×
Ten-year median
0.0×
Current reading's percentile
98
P/E ratio against peers
| Company | P/E ratio |
|---|---|
| KURA Kura Oncology, Inc. compare | n/m |
| HELP Cybin Inc. compare | n/m |
| DSGN Design Therapeutics, Inc. compare | n/m |
| DBVT DBV Technologies S.A. compare | n/m |
| FDMT 4D Molecular Therapeutics, Inc. compare | n/m |
| AVBP ArriVent BioPharma, Inc. compare | n/m |
| IMMX Immix Biopharma, Inc. compare | n/m |
| GERN Geron Corporation | n/m |
| CADL Candel Therapeutics, Inc. compare | n/m |
| Biotechnology industry median | 10.6× |
| Healthcare sector median | 24.5× |
| Market median | 17.8× |
What P/E ratio is
Price to Earnings Ratio shows how much investors pay for each dollar of a company’s annual profit per share.
Stock Price ÷ EPS (Basic) (TTM)